
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Thymosin Beta-4 (TB-500) is a synthetic peptide derived from the naturally occurring 43-amino acid protein thymosin β4. It promotes tissue repair and wound healing by enhancing cell migration, angiogenesis, and reducing inflammatory cytokine expression.

Reported Benefits (Provisional)
Origin & History

Thymosin Beta-4 (TB-500) is a synthetic version of a naturally occurring peptide involved in tissue repair and regeneration. It is produced through peptide synthesis, ensuring high purity for therapeutic use.
Research Narrative (Provisional)
Animal studies and preliminary human research highlight TB-500's role in tissue repair and inflammation reduction. More clinical trials are needed to establish its efficacy in humans.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Composed of 43 amino acids. - Contains no calories, fats, or carbohydrates. - Available in injectable form for targeted delivery.
Reported Mechanism (Provisional)
TB-500 binds to actin proteins and promotes actin polymerization, facilitating cell migration and tissue remodeling. It upregulates VEGF (vascular endothelial growth factor) expression to stimulate angiogenesis and new blood vessel formation. The peptide also modulates inflammatory pathways by reducing pro-inflammatory cytokines like TNF-α and IL-1β while promoting anti-inflammatory mediators.
Clinical Narrative (Provisional)
Most research on TB-500 consists of preclinical animal studies rather than large-scale human trials. Animal studies have demonstrated accelerated wound healing, improved muscle regeneration, and reduced inflammation with dosages typically ranging from 2-10mg administered twice weekly. Limited human case reports suggest potential benefits for injury recovery, but controlled clinical trials in humans are lacking. The current evidence base is promising but insufficient to establish definitive therapeutic protocols or safety profiles in humans.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







